Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMV2Y6L)

• Drug Name: Alinidine Drug Info
• Synonyms: ST-567

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Discontinued in Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 36354
  CAS Number: CAS 33178-86-8
  TTD Drug ID: DMV2Y6L

Molecule-Related Drug Atlas

Drug(s) Targeting Potassium channel unspecific (KC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nateglinide	DMLK2QH	Diabetic complication	5A2Y	Approved	[4]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[4]
Dronedarone	DMA8FS5	Angina pectoris	BA40	Approved	[5]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[4]
Amifampridine	DMK08L3	LambertEaton myasthenic syndrome	8C62	Approved	[6]
Minoxidil	DMA2Z4F	Alopecia	ED70	Approved	[4]
Pinacidil	DMRADYL	High blood pressure	BA00	Approved	[4]
Dalfampridine	DMM0PDO	Multiple sclerosis	8A40	Approved	[7]
Ibutilide	DMKXY2R	Atrial fibrillation	BC81.3	Approved	[4]
Diazoxide	DML1538	Congenital hyperinsulinism	5A4Y	Approved	[4]

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[8]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[9]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[10]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[11]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[11]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[12]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[13]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[14]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[15]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Blocker	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Gene/Protein Processing	[3]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000286)
• [2] Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):210-3.
• [3] Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [6] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [7] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [8] Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
• [9] Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
• [10] Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
• [11] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
• [12] Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
• [13] Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
• [14] Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
• [15] Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.